meta|evidence COVID-19
  • Living systematic review and meta-analysis
  • ***** adjuvant therapies
  • anti-inflammatoty and immuno-therapy
  • Immunosuppressants drugs
  • abatacept
  • adalimumab
  • anakinra
  • anti-interleukin-6
  • canakinumab
  • cenicriviroc
  • complement inhibitors
  • CRAC-channel inhibitors (auxora)
  • eculizumab
  • emapalumab
  • fostamatinib
  • infliximab
  • itolizumab
  • ixekizumab
  • jakotinib
  • janus kinase (JAK) inhibitor
  • lenzilumab
  • pamrevlumab
  • tacrolimus
  • tetrandrine
  • thalidomide
  • ***** antiandrogenic
  • ***** antiviral and associated therapy
  • ***** control
  • ***** Drugs for acid related disorders
  • ***** miscellaneous
  • ***** Oral antidiabetic drugs
  • ***** Renin-angiotensin-system-acting agents
  • ***** vaccines
  • ***** Vitamins
  • COVID 19 hospitalized
  • COVID 19 all comers
  • COVID-19 mild to moderate
  • COVID-19 severe or critically
  • COVID 19 outpatients
  • COVID-19 (hospitalized or not)
  • COVID-19 prophylaxis (children)
  • COVID-19 prophylaxis (excluding children)
  • infections other than COVID-19
  • Long COVID-19
  • preventing respiratory virus transmission
  • secondary prevention